In March 2016 a number of direct acting antiviral medications for the treatment of chronic hepatitis C infection were made available on the Pharmaceutical Benefits Scheme. These medications are highly effective, curing over 95 percent of those treated, have little or no adverse side effects and are easily self-administered. General …
New hepatitis C treatments achieving incredible results
When the new treatments for chronic hepatitis C were released in 2016 they were touted as a game-changer. Many of us watched with cautious optimism. Would the Department of Health’s expensive gamble to eradicate hepatitis C pay off? The fact is, the new Direct Acting Antivirals (DAAs) are achieving incredible …